Lytix Biopharma AS (OL:LYTIX) — Stock Price
Lytix Biopharma AS (OL:LYTIX) is currently trading at Nkr7.58 NOK, down 10.82% today. Over the past 52 weeks, shares have ranged between Nkr6.90 and Nkr11.50. This page tracks Lytix Biopharma AS's live share price on the OL exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market cap of Lytix Biopharma AS.
Lytix Biopharma AS (LYTIX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Lytix Biopharma AS's daily closing share price and trading volume on the OL exchange over the past year, giving a clear view of recent price momentum and liquidity.
Lytix Biopharma AS Income Statement — Revenue, Profit & Earnings by Year
Lytix Biopharma AS's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | Nkr0.00 | Nkr11.13 Million | Nkr3.99 Million | Nkr1.41 Million | Nkr17.00K |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | Nkr13.80 Million | Nkr72.56 Million | Nkr63.17 Million | Nkr50.97 Million | Nkr28.82 Million |
| SG&A | Nkr32.62 Million | Nkr22.59 Million | Nkr24.34 Million | Nkr21.13 Million | Nkr31.61 Million |
| Total Operating Expenses | Nkr64.03 Million | Nkr107.03 Million | Nkr100.78 Million | Nkr67.11 Million | Nkr48.03 Million |
| Operating Income | Nkr-64.03 Million | Nkr-95.90 Million | Nkr-96.78 Million | Nkr-65.69 Million | Nkr-48.02 Million |
| EBITDA | — | — | — | Nkr-55.92 Million | Nkr-48.05 Million |
| EBIT | — | — | — | Nkr-65.70 Million | Nkr-48.02 Million |
| Interest Expense | Nkr211.00K | Nkr126.00K | Nkr56.00K | Nkr55.00K | Nkr3.00K |
| Income Before Tax | Nkr-59.98 Million | Nkr-94.27 Million | Nkr-87.90 Million | Nkr-56.01 Million | Nkr-48.05 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | Nkr-59.98 Million | Nkr-94.27 Million | Nkr-87.90 Million | Nkr-56.01 Million | Nkr-48.05 Million |
Lytix Biopharma AS Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Lytix Biopharma AS's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | Nkr81.52 Million | Nkr146.53 Million | Nkr63.87 Million | Nkr152.02 Million | Nkr202.96 Million |
| Total Current Assets | Nkr79.44 Million | Nkr143.90 Million | Nkr63.33 Million | Nkr151.89 Million | Nkr202.96 Million |
| Cash & Equivalents | Nkr10.60 Million | Nkr130.79 Million | Nkr27.36 Million | Nkr94.55 Million | Nkr197.28 Million |
| Short-term Investments | Nkr61.76 Million | Nkr0.00 | Nkr23.18 Million | Nkr50.61 Million | — |
| Net Receivables | — | Nkr458.00K | Nkr0.00 | Nkr6.00 Million | Nkr5.13 Million |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | Nkr2.09 Million | Nkr2.63 Million | Nkr548.00K | Nkr124.00K | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | Nkr19.77 Million | Nkr38.64 Million | Nkr12.55 Million | Nkr16.89 Million | Nkr13.34 Million |
| Total Current Liabilities | Nkr18.55 Million | Nkr36.76 Million | Nkr12.51 Million | Nkr16.89 Million | Nkr13.34 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | Nkr61.75 Million | Nkr107.89 Million | Nkr51.32 Million | Nkr135.13 Million | Nkr189.62 Million |
| Retained Earnings | — | — | — | — | — |
Lytix Biopharma AS Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Lytix Biopharma AS generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | Nkr-59.85 Million | Nkr-70.37 Million | Nkr-95.97 Million | Nkr-52.10 Million | Nkr-44.90 Million |
| Capital Expenditures | Nkr0.00 | Nkr0.00 | Nkr49.00K | Nkr154.00K | Nkr154.00K |
| Free Cash Flow | Nkr-59.85 Million | Nkr-70.37 Million | Nkr-96.02 Million | Nkr-52.26 Million | Nkr-44.90 Million |
| Investing Cash Flow | Nkr-59.43 Million | Nkr24.69 Million | Nkr29.73 Million | Nkr-50.76 Million | Nkr-50.76 Million |
| Financing Cash Flow | Nkr-908.00K | Nkr149.11 Million | Nkr-943.00K | Nkr133.00K | Nkr213.73 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | Nkr13.84 Million | Nkr878.00K | Nkr4.18 Million | Nkr1.38 Million | Nkr4.05 Million |
| Depreciation | Nkr1.00 Million | Nkr915.00K | Nkr962.00K | Nkr30.00K | Nkr30.00K |
| Change in Cash | Nkr-120.19 Million | Nkr103.43 Million | Nkr-67.19 Million | Nkr-102.73 Million | Nkr168.83 Million |
Lytix Biopharma AS Earnings History — EPS Actual vs. Analyst Estimates
Track Lytix Biopharma AS's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 21, 2026 | — | — | — |
| Feb 12, 2026 | -0.27 | — | — |
| Nov 18, 2025 | — | — | — |
| Aug 28, 2025 | -0.07 | — | — |
| May 15, 2025 | -0.19 | — | — |
| Feb 13, 2025 | -0.54 | — | — |
| Nov 19, 2024 | -0.46 | — | — |
| Aug 29, 2024 | -0.48 | — | — |